Clinical Trial Results: A Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC [Phase 2]

View source ↗

Summary

Phase 2 study evaluating patidegib topical gel 2% for reducing disease burden in patients with recurrent basal cell carcinoma; study terminated with results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Basal Cell Carcinoma

Drugs mentioned

• Patidegib topical gel 2% (patidegib)

Snippet

Sponsor: Sol-Gel Technologies, Ltd. | Conditions: Recurrent Basal Cell Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2026-07-21